齐拉西酮序贯治疗的临床观察

齐拉西酮、氯氮平联合碳酸锂治疗躁狂症的临床效果观察李风平(河南省驻马店市精神病医院，河南驻马店463000)摘要目的对齐拉西酮、氯氮平联合碳酸锂治疗躁狂症的临床效果进行探讨。

方法本研究对象118例躁狂症患者，采用盲选法将患者平均分为两组，其中59例采用氯氮平联合碳酸锂治疗的患者纳入对照组，另外59例采用齐拉西酮联合碳酸锂治疗的患者纳入观察组，比较两组患者治疗效果及狂躁症状评分情况。

结果观察组患者的治疗有效率为94.9%,显著高于照组80.0%(!<0.05);治疗前，两组患者BRMS评分无统计学差异(P>0.05);药物治疗后，两组患者的BRMS评分均有下降，且观察组下降幅度明显大于对照组(！<0.05)。

结论针对躁狂症患者，与氯氮平联合碳酸锂治疗相比较，使用齐拉西酮联合碳酸锂治疗效果更显著，患者的狂躁，极具临床c关键词齐拉西酮；氯氮平;碳酸锂;躁狂症[中图分类号]R749.3[文献标识码]B学科分类代码：32024文章编码:1001-8131(2020)02-0151-02躁狂症是临床见的一种精神疾病,患者常岀现情绪亢奋、高度兴奋易激怒的情况，严重时甚至岀现妄想抑郁的双向障碍，患者逐渐失去自主情感掌控能力，身心健康受到极，给家庭社会带来负担叽该种疾的患病因尚不明确，但专家者经反复调查与研究得岀，疾心化遗传因。

临床上治疗躁狂症的药物多，但患者个体，因治疗效果不叫为一西酸锂药物对治疗躁狂症患者的临床疗效、躁狂症情况及副反应情况，本文以表2不良反应情况比较组别(n=30)对照组观察组心P[脱发137 2.70>0.05恶心呕吐812 1.20>0.05腹泻26 1.29校正>0.05骨髓抑制650.11>0.05肝功能异常710 1.27>0.05视觉异常18 4.71校正<0.05长因子受体(EGFR)和间变性淋巴瘤激酶(ALK)突变，其中针对ALK的第一代靶向药物就是克M 替尼。

碳酸锂缓释片联合齐拉西酮序贯治疗双相障碍躁狂发作对照研究杨珊珊;张程赪【期刊名称】《临床心身疾病杂志》【年(卷),期】2016(22)6【摘要】Objective To explore the efficacy and safety of lithium carbonate sustained‐release tablets (LCSRTs) plus ziprasidone sequential treatment for manic episode of bipolar disorder (MEBD) .Methods A total of 100 MEBD patients were randomly divided into two groups of 50 oneseach ,both groups took o‐rally LCSRTs ,observation was plus ziprasidone sequential treatment and control group plus oral quetiap‐ine for 8 weeks .Efficacies were assessed with the Bech‐Rafaelsen Mania Rating Scale (BRMS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results Since the end of the 1st week the BRMS scores of both groups lowered more significantly compared with pretreatment (P<0 .01) ,that was significantly lower in observation than in control group at the end of the 2nd week (P<0 .05);at the end of the 8th week the total effective rate was respectively 92 .0% in observa‐tion and 90 .0% in control gro up ,which showed no significant group difference (P>0 .05) .Adverse reac‐tions of both groups weremild ,the incidences of adverse reactions was 44 .0% in observation group ,that of ECG abnormality higher ;the incidences of adverse reactionswas 48 .0% in control group ,those of men‐struation changes and lactation were higher .There was no significant group difference in the incidence of adverse reactions (P>0 .05) .Conclusion LCSRTs plus ziprasidone sequential treatment for MEBD take effect more rapidly and have an evident effect and higher safety .%目的：探讨碳酸锂缓释片联合齐拉西酮序贯治疗双相障碍躁狂发作的临床疗效和安全性。